osteonecrosis

(redirected from bisphosphonate-associated osteonecrosis)
Also found in: Medical.
Translations

os·te·o·ne·cro·sis

n. osteonecrosis, destrucción y deteorización completa de tejido óseo.

osteonecrosis

n osteonecrosis f
References in periodicals archive ?
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
INTRODUCTION: Bisphosphonate-associated osteonecrosis of the jaw, often abbreviated as BON, BON of the jaw or even BRONJ, is a recently discovered dental phenomenon that may lead to surgical complication in the form of impaired wound healing following oral or periodontal surgery or endodontic therapy.
Bisphosphonate-associated osteonecrosis of the jaw: A literature review and clinical practice guidelines.
Actinomycosis of bone is a rare disease that usually result from adjacent soft tissue infection, but may be also associated with trauma, infected osteoradionecrosis, bisphosphonate-associated osteonecrosis and invation of microorganisms throught out periodontal ligament.
Bisphosphonate-associated osteonecrosis of the jaw (BON) is defined as the unexpected development of necrotic bone in the oral cavity of a patient who is receiving bisphosphonate treatment and has not received radiotherapy to the head and neck.
Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the patient has undergone dental surgery.
Drug manufacturers and the US Food and Drug Administration have issued warnings about possible bisphosphonate-associated osteonecrosis of the jaw.
release of guidelines on diagnosis, risk identification, prevention, and management of bisphosphonate-associated osteonecrosis of the jaw
WASHINGTON -- It's better to prevent bisphosphonate-associated osteonecrosis of the jaw than to have to treat this rare disorder.
In 2003, dentists started to see patients with a serious bone disease, bisphosphonate-associated osteonecrosis of the jaw (BON).
Canadian consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw.
As the discussions of the association between BIS drug therapy and ONJ have emerged, another anachronism has been proposed, namely bisphosphonate-associated osteonecrosis of the jaw (BON).